Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy

Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy

Newro Foundation research team, Prof David Walker, Neurosurgeon and Beth Morrison, Clinical Research & Development Manager, have been working in collaboration with the School of Medicine, QIMR and the Department of Pathology, Hong Kong to research the impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy.

Objectives. Clinical response to antibody-based immunotherapies
targeting checkpoint inhibitors is critically dependent on the
tumor immune microenvironment (TIME). However, the precise
impact of the TIME on adoptive cellular immunotherapy remains
unexplored. Here we have conducted a long-term follow-up
analysis of patients with recurrent glioblastoma multiforme (GBM)
who were treated with autologous CMV-specific T-cell therapy to
delineate the potential impact of the TIME on their clinical
response.

We are excited to announce, the paper has recently been published by the Australian and New Zealand Society for Immunology Inc. Click here to read the full publication.

Loading...